Abstract
Background. A key link in the pathogenesis of atopic dermatitis is a violation of the barrier function of the skin. Artificial skin moisturizing with emollients is the basis of palliative therapy for the disease.
 Aims. The purpose of the study was to assess the effectiveness and tolerability of the cosmetic product Admera.
 Materials and methods. The article presents the results of an open non-comparative prospective observational study of the efficacy and safety of Admera cream in pediatric patients with mild to moderate atopic dermatitis, conducted at the Pierre Wolkenstein Clinic for Skin Diseases in June-August 2020.
 Results. The study included 35 patients aged 4 to 17 years. The study included 35 patients aged 4 to 17 years inclusive. The clinical study demonstrated a statistically significant decrease in the Severity scoring of atopic dermatitis (SCORAD) index total score. The average value of this indicator decreased by 33% from the value 36.2 12.3 at the screening visit to 24.2 11.4 at the visit 3 (p 0.001). Assessment of the dynamics of the Eczema area and severity index (EASI) index showed a significant decrease in the total score of the indicator after 14 and 28 days of therapy relative to the baseline (p 0.001). The cosmetic product studied was well tolerated by patients. During the present study, 3 adverse events were reported in 2 patients. According to expert opinion, the recorded undesirable phenomena were not associated with the application of the studied cosmetic product. Reported adverse events were gastrointestinal disorders and included cases of diarrhea, abdominal pain and at the end of the study completely
 Conclusions. Evaluation of the results of the study showed high efficacy and safety of the study drug as a moisturizing agent: four-week therapy leads to a decrease in the severity of Atopic dermatitis manifestations, a decrease in the intensity of pruritus, an increase in the level of skin hydration in the T-zone and on the patient's body.
Highlights
A key link in the pathogenesis of atopic dermatitis is a violation of the barrier function of the skin
The article presents the results of an open non-comparative prospective observational study of the efficacy and safety of Admera cream in pediatric patients with mild to moderate atopic dermatitis, conducted at the Pierre Wolkenstein Clinic for Skin Diseases in June-August 2020
Assessment of the dynamics of the Eczema area and severity index (EASI) index showed a significant decrease in the total score of the indicator after 14 and 28 days of therapy relative to the baseline (p < 0.001)
Summary
A key link in the pathogenesis of atopic dermatitis is a violation of the barrier function of the skin. Целью клинического исследования являлась оценка эффективности и переносимости косметического средства Адмера (крем) при регулярном применении в составе комплексной терапии у детей с атопическим дерматитом. У всех пациентов были оценены исходные параметры, необходимые для последующей оценки эффективности терапии (медианы значений): индекс SCORAD (34,9 балла), индекс EASI (5,5 балла), шкала IGA (2,5 балла), шкала ВАШ для оценки ксероза (5 баллов), индекс ТЭПВ (от 29 до 33 г/м2/ч на различных участках кожи), показатель корнеометрии Оценка поражения кожи и тяжести атопического дерматита, проведенная по индексу IGA, показала, что на скрининге средний балл по шкале составил 2,5 ± 0,4: у 11% пациентов была зарегистрирована практически чистая кожа (степень 1), у 32% — легкая степень тяжести (степень 2), у оставшихся 57% — средняя степень тяжести основного заболевания (степень 3). Уже через 2 недели терапии интенсивность ксероза оценивалась на 1 балл у 5,7% пациентов (на скрининге на 1 балл не был оценен ни один случай ксероза), при этом максимальное значение оценки по ВАШ
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
